DMAC vs LIN · $157.4M cap vs P/E 34, rev $33.99B
DiaMedica Therapeutics Inc (DMAC) versus Linde plc Ordinary Shares (LIN) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
DMAC does not have a complete income-statement cache yet.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
DMAC currently screens at market cap $157.4M. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Not investment advice. Open the DMAC and LIN stock pages for the full models.
Not investment advice.